Simulations Plus Incorporated (NASDAQ:SLP) had a decrease of 1.59% in short interest. SLP’s SI was 259,600 shares in February as released by FINRA. Its down 1.59% from 263,800 shares previously. With 28,800 avg volume, 9 days are for Simulations Plus Incorporated (NASDAQ:SLP)’s short sellers to cover SLP’s short positions. The SI to Simulations Plus Incorporated’s float is 2.37%. The stock increased 1.59% or $0.25 during the last trading session, reaching $15.95. About 115,123 shares traded or 124.25% up from the average. Simulations Plus, Inc. (NASDAQ:SLP) has risen 48.65% since February 11, 2017 and is uptrending. It has outperformed by 31.95% the S&P500.
Analysts expect Regenxbio Inc. (NASDAQ:RGNX) to report $-0.71 EPS on March, 6.They anticipate $0.03 EPS change or 4.05% from last quarter’s $-0.74 EPS. After having $-0.67 EPS previously, Regenxbio Inc.’s analysts see 5.97% EPS growth. The stock increased 0.78% or $0.2 during the last trading session, reaching $25.7. About 276,438 shares traded. Regenxbio Inc. (NASDAQ:RGNX) has risen 51.43% since February 11, 2017 and is uptrending. It has outperformed by 34.73% the S&P500.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. The company has market cap of $800.43 million. The Company’s gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. It currently has negative earnings. The company's lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration.
Among 4 analysts covering Regenxbio (NASDAQ:RGNX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Regenxbio had 4 analyst reports since October 12, 2015 according to SRatingsIntel. The firm has “Overweight” rating given on Monday, October 12 by Piper Jaffray. The company was initiated on Monday, October 12 by Bank of America. Morgan Stanley initiated Regenxbio Inc. (NASDAQ:RGNX) on Tuesday, October 13 with “Overweight” rating. On Tuesday, October 20 the stock rating was initiated by Chardan Capital Markets with “Buy”.
Simulations Plus, Inc. develops and sells drug discovery and development software for mechanistic modeling and simulation. The company has market cap of $275.82 million. The firm offers GastroPlus, which simulates the absorption, pharmacokinetics , and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. It has a 45.57 P/E ratio. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry computer program, which takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher that integrates with MedChem Studio and ADMET Predictor.